title: [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
abstract: OBJECTIVE
  To explore the clinical implication of soluble interleukin-6 receptor(sIL-6R) in patients with malignant hematological diseases.
  
  
  METHODS
  Serum levels of sIL-6R in 26 multiple myeloma (MM), 34 acute leukemia (AL) and 17 non-Hodgkin's lymphoma (NHL) patients before and after chemotherapy and 20 normal controls were measured by immunoenzymetic assay.
  
  
  RESULTS
  Serum levels of sIL-6R in MM and B-ALL patients at diagnosis were significantly higher than that in normal controls (P < 0.001, and P < 0.01, respectively), while the levels in ANLL, T-ALL and NHL patients were normal. Serum beta2 microglobulin and creatinine levels in MM patients with elevated serum sIL-6R were higher than that in patients with normal sIL-6R levels(P < 0.001, and P < 0.05, respectively). Serum sIL-6R levels did not relate to clinical stages. Serum lactic-dehydrogenase (LDH) levels in B-ALL patients with elevated sIL-6R were higher than that in patients with normal sIL-6R levels (P < 0.05). Serial measurement of serum sIL-6R in MM patients showed a good correlation with serum M-protein and plasma cell percentage in bone marrow.
  
  
  CONCLUSIONS
  Serum sIL-6R levels were significantly increased in MM and B-ALL patients, and it is a predictive factor for responsiveness to chemotherapy and an indicator of disease activity.
authors.affiliation: Department of Hematology, Affiliated Hospital of Weifang Medical College, Weifang 261031.
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: W
authors.initials: W
authors.lastname: Cui
authors.forename: C
authors.initials: C
authors.lastname: Ma
authors.forename: C
authors.initials: C
authors.lastname: Ma
authors.forename: E
authors.initials: E
authors.lastname: Ji
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D006402:Hematologic Diseases / Q000097:blood* / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000097:blood* / Q000737:chemistry*; D012995:Solubility; D016896:Treatment Outcome
chemical_list: D019947:Receptors, Interleukin-6